(Q33393378)

English

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

John B A G Haanen

3

object named as

John Haanen

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Viktor Grünwald

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ingrid M E Desar

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Walter Fiedler

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ulrik Mouritzen

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M W Brændholt Olsen

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carla M L van Herpen

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Acta Oncologica

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

121-126

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Interleukin 21: combination strategies for cancer therapy

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

IL-21 induces the functional maturation of murine NK cells

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

A critical role for IL-21 in regulating immunoglobulin production

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Update on the application of interleukin-2 in the treatment of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Cytokine-receptor pairing: accelerating discovery of cytokine function

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Interleukin-21 signaling: functions in cancer and autoimmunity

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2010.509104

21 January 2018

Identifiers

10.3109/0284186X.2010.509104

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33393378&oldid=2142063965"